An important therapeutic mechanism of allogeneic hematopoietic SCT (HSCT) is the antileukemic immune response, the so-called GVL effect, which is thought to be mediated mainly by alloreactive T and natural killer cells. 1 As a consequence of immunological disturbance after HSCT, autoimmune hemolytic anemia, immune thrombocytopenia and autoimmune neutropenia (AIN) are sometimes observed in association with GVHD. 2 However, the relationship between GVHD, GVL effect and autoimmune disorders is poorly understood. Here, we present a rare case of the simultaneous occurrence of severe AIN and a smoldering relapse of myeloid/natural killer-cell precursor acute leukemia after allogeneic HSCT. Interestingly, immunocytochemical studies revealed serum reactivity to leukemic cells, indicating the direct suppressive effects of autoantibodies on leukemic cells. This report illustrates the possibility of a novel mechanism of the GVL effect mediated by autoantibody generation.
A 34-year-old man with myeloid/natural killer-cell precursor acute leukemia 3 in first CR received BMT from an HLA-identical unrelated donor (8/8 matched by highresolution techniques) following conditioning with CY and fractionated TBI (12 Gy). The GVHD prophylaxis consisted of CsA and short-term MTX. The post transplant course was uneventful without acute GVHD, and six months after BMT, CsA was discontinued and remission was maintained. Ten months after transplantation, sclerodermatous chronic GVHD gradually appeared, and two months later, the neutrophil count suddenly fell to 0.17 Â 10 9 /l. His clinical course is summarized in Figure 1 . Repeated BM examination showed the infiltration of blastic cells with varying proportions from 11 to 88% among the nucleated marrow cells, but these blastic cells spontaneously decreased below 5% one month after the onset of neutropenia. Severe neutropenia persisted and the BM showed a gradual decrease of cellularity, especially in mature myeloid cells. Five months later, the platelet counts and hemoglobin level also declined gradually, and 22 months after BMT, the platelet count fell to 8 Â 10 9 /l. His general condition was very good during this period, without any specific treatments including myeloid growth factors. Thrombocytopenia was refractory to platelet transfusions and investigation for autoimmune-mediated cytopenia was performed. Laboratory examinations revealed polyclonal hypergammaglobulinemia and slightly elevated platelet-associated IgG, and the assessment of platelet-binding IgG resulted in a positive pattern on the mixed hemagglutination test. As for neutrophils, the granulocyte indirect immunofluorescence test (GIIFT) was performed using human neutrophil antigen (HNA)-typed neutrophils, as described previously. 4, 5 GIIFT detected a high titer of antineutrophil antibody (ANA) in the patient's serum, providing evidence of AIN. The patient's serum reacted strongly against HNA-1a-homo- zygous neutrophils (Figure 2a) , HNA-1b-homozygous neutrophils ( Figure 2b ) and neutrophils from an FcgRIIIb-deficient donor (data not shown). The target antigens of the autoantibodies were not specified and the anti-HLA antibodies were not identified. On the other hand, extensive investigation of leukemic relapse detected extramedullary lesions around the sternum and limbs. Furthermore, retrospective chimerism examination of the BM sample at the onset of neutropenia identified recipient cells in 20% of the BM cells, confirming that the relapse had already occurred at this point. However, a significant progression of leukemia was not observed thereafter.
Although a clinical relapse of leukemia was recognized, the administration of intensive chemotherapy was withheld because of the persistent, severe cytopenia. Therefore, treatment for autoimmune cytopenia was attempted first. We chose high-dose dexamethasone therapy (40 mg/body, peroral, days 1-4) followed by prednisolone at 5 mg/day. One cycle of the high-dose dexamethasone therapy rapidly increased the platelet count to 100 Â 10 9 /l, and the hemoglobin level also elevated. After the second cycle, the neutrophil count temporarily increased up to 0.35 Â 10 9 /l but soon fell, and this time leukemic infiltration became prominent in the peripheral blood and BM. As GIIFT showed that ANA had almost completely disappeared from the patient's serum at this point, the decreased neutrophil count was thought to be due to leukemic infiltration. After salvage chemotherapy, consisting of cytarabine, etoposide and mitoxantrone, CR was confirmed and the neutrophil Immunocytochemical studies show that leukemic blasts were positively stained by the patient's previous serum sample (brown) (c). The patient's BM specimen with an extensive infiltration of blasts was stained by the previous serum sample collected before the high-dose dexamethasone treatment (c) and the healthy donor's serum (d) at a 1:25 dilution, respectively. Peroxidase-conjugated anti-human IgG was used as a secondary antibody. As a negative control, a tonsillar lymph node specimen from a healthy man was stained by the patient's previous serum sample (e) and the healthy donor's serum (f). There was no significant staining in these specimens (e and f). GIIFT ¼ granulocyte indirect immunofluorescence test; HNA ¼ human neutrophil antigen. count increased to more than 0.5 Â 10 9 /l for the first time after the onset of neutropenia.
Neutropenia following allogeneic HSCT can be caused by graft rejection, intrinsic graft failure, infection, GVHD, a relapse of the underlying disease or drug-induced myelosuppression. 6 Although leukemia recurrence was initially considered to bring about neutropenia in this case, GIIFT revealed the production of ANA as a cause of neutropenia. Although very little is known about the pathogenesis of AIN after HSCT, it could be theoretically induced by two different mechanisms: alloantibody production by residual host plasma cells, caused by incompatibility of the neutrophil alloantigen and HLA systems, or an autoimmune mechanism similar to secondary AIN in systemic autoimmune disease. 6 In the latter mechanism, donor plasma cells could produce antibodies directed against donor neutrophils. Considering the kinetics of plasma cell chimerism after HSCT, 7 AIN by the alloimmune mechanism can be possible in the early stage after HSCT, and a case with graft failure caused by anti-HNA2a antibodies has actually been reported. 8 On the other hand, AIN by the autoimmune mechanism could occur with a late onset in relation to chronic GVHD, as supported by reports on the occurrence and association of autoantibodies in chronic GVHD. 9, 10 The involvement of T-cell-mediated immunoderangement has been suggested as the etiology of AIN in some cases. On the basis of these considerations, AIN in our patient seems to have been mediated by an autoimmune mechanism rather than alloreaction.
However, it is difficult to explain why the relapsed leukemia did not show significant progression without any specific treatment over about one year after neutropenia onset. To better understand the pathogenesis of AIN in our case, an additional factor should also be considered: relapse of the underlying leukemia. To examine the effect of ANA on the slow progression of the underlying leukemia, the interaction between ANA and the leukemic blasts was further investigated. Immunocytochemical analysis using the patient's previous serum sample containing a high titer of ANA and the BM specimen containing numerous blasts showed that the blasts were positively stained by the patient's previous serum sample (Figure 2c-f) . This serum reactivity to the leukemic cells raised the possibility that ANA in the patient recognized the leukemic cells and inhibited disease progression by antibody-mediated effector mechanisms such as complement-mediated and antibodydependent cellular cytotoxicity. The autoimmune process might involve a specific GVL reaction to residual leukemic cells in addition to carrying out an immune attack on donor-derived hematopoietic cells. This hypothesis is supported by the clinical course, which showed that AIN activity was inversely correlated with the progression of leukemia under high-dose dexamethasone therapy. To the best of our knowledge, our report is the first to demonstrate a potential functional link between autoimmune cytopenia and the antileukemic immune response. Although the immunological mechanism of autoantibody production should be further investigated, this intriguing case demonstrates the possibility of a GVL effect driven by autoantibody production. 
